ReviewFrontiers in pharmacology2025
Research and application of medicines for treating liver fibrosis: current status and prospects.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular and Regenerative Effects of Platelet-Rich Plasma and Related Hemocomponents in Animal Models of Liver Injury-A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Aloin attenuates high-glucose-induced oxidative and inflammatory damage in renal cells via AMPK/Nrf2 signaling.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Unveiling the Immunopharmacological Mechanisms of Biejiajian Pills (BJJP) Underlying the Treatment of Hepatic Fibrosis: Insights From Network Pharmacology and Experimental Validation.Food science & nutrition · 2026Article
- From diet to disease modulation: the multi-targeted effects of medicinal-food homologous plants in hepatic fibrosis.Frontiers in nutrition · 2026Review
- Acetylbinankadsurin A Decreases Macrophage Glycolysis and Pro-Inflammatory Phenotype Polarization via Inhibiting HIF-1α to Alleviate Hepatic Fibrosis in Mice.Molecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethnopharmacological Relevance: Liver fibrosis is a common pathological consequence of multiple chronic liver diseases, making its pharmacological management a key area of medical research. Diverse classes of therapeutic agents offer distinct advantages and limitations. Notably, combination therapy has emerged as a prominent focus of contemporary investigation due to its potential to enhance treatment outcomes. Materials and Methods: As of 1 February 2025, a comprehensive literature search was conducted using PubMed and Web of Science, employing keywords related to liver fibrosis and its treatment. In accordance with ConPhyMP guidelines, one author assessed the quality of studies involving botanical drug metabolites. Results: This review synthesizes findings from 111 research articles, offering an overview of two primary classes of therapeutic agents and their integration with emerging technologies-namely mesenchymal stem cell-derived exosomes and nanoparticles. On one side, it discusses biomedicine-related therapies, including conventional biomedicine medicines, repurposed drugs, and investigational compounds. On the other, it addresses botanical-based treatments, encompassing traditional Chinese medicine (TCM) formulas and botanical drug metabolites. Both categories have shown promising therapeutic efficacy in clinical and preclinical settings. Conclusion: This review provides a comprehensive and detailed overview of pharmacological strategies for the treatment of liver fibrosis, shows the application and research status of different types of medicines, and provides a comprehensive perspective for current research directions. It points out the limitations of existing research and suggests that the clinical research of various medicines and combination therapies should be strengthened in the future, and the liver fibrosis model should be optimized to promote clinical transformation, which provides an important reference for future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.